Skip to main content

CORRECTION article

Front. Immunol., 27 September 2018
Sec. B Cell Biology
Volume 9 - 2018 | https://doi.org/10.3389/fimmu.2018.02218
This article is part of the Research Topic Making Science Fun – A Tribute to Our Colleague and Friend, Prof. Antonius G. Rolink (1953–2017) View all 18 articles

Corrigendum: Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance

This article is a correction to:

  1. Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance

    1. Read original article
\r\nSarah A. GreavesSarah A. Greaves1Jacob N. PetersonJacob N. Peterson1Raul M. Torres,Raul M. Torres1,2Roberta Pelanda,*Roberta Pelanda1,2*
  • 1Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States
  • 2Department of Biomedical Research, National Jewish Health, Denver, CO, United States

A Corrigendum on
Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance

by Greaves SA, Peterson JN, Torres RM, Pelanda R. Front. Immunol. (2018) 9:707. doi: 10.3389/fimmu.2018.00707

In the original article, a mistake was found in affiliation 1. The state should be CO (Colorado) instead of IL (Illinois). The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: B cells, B cell tolerance, BCR signaling, MAP kinase, ERK, B cell development, autoreactive B cells, mouse models

Citation: Greaves SA, Peterson JN, Torres RM and Pelanda R (2018) Corrigendum: Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance. Front. Immunol. 9:2218. doi: 10.3389/fimmu.2018.02218

Received: 15 August 2018; Accepted: 06 September 2018;
Published: 27 September 2018.

Approved by:

Frontiers in Immunology Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2018 Greaves, Peterson, Torres and Pelanda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Roberta Pelanda, cm9iZXJ0YS5wZWxhbmRhQHVjZGVudmVyLmVkdQ==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.